Levodopa-induced myocardial infarction in a patient with Parkinson’s disease and severe coronary artery disease

Chen Fei Ng, Patrick W.J. Tiau, Hui Jan Tan, Norlinah Mohamed Ibrahim

Research output: Contribution to journalArticle

Abstract

Levodopa is the most effective medical treatment for Parkinson’s disease (PD) to date. As dopamine is known to increase cardiac inotropism and vasomotor tone, peripheral dopamine decarboxylase inhibitor is coadministered to suppress the peripheral conversion of levodopa to dopamine. Levodopa poses potential cardiovascular risks, thus its use in patients with existing coronary artery disease needs to be carefully monitored. We report a case of an elderly male with newly diagnosed PD who developed non-ST-elevation myocardial infarction following levodopa (Madopar) initiation.

Original languageEnglish
Pages (from-to)37-39
Number of pages3
JournalJournal of the Royal College of Physicians of Edinburgh
Volume49
Issue number1
DOIs
Publication statusPublished - 1 Mar 2019

Fingerprint

Disease
physician's care

Keywords

  • Coronary artery disease
  • Levodopa
  • Myocardial infarction
  • Parkinson’s disease

ASJC Scopus subject areas

  • Education

Cite this

@article{7eefa10d156a4c65b8cb81cbf5a75d16,
title = "Levodopa-induced myocardial infarction in a patient with Parkinson’s disease and severe coronary artery disease",
abstract = "Levodopa is the most effective medical treatment for Parkinson’s disease (PD) to date. As dopamine is known to increase cardiac inotropism and vasomotor tone, peripheral dopamine decarboxylase inhibitor is coadministered to suppress the peripheral conversion of levodopa to dopamine. Levodopa poses potential cardiovascular risks, thus its use in patients with existing coronary artery disease needs to be carefully monitored. We report a case of an elderly male with newly diagnosed PD who developed non-ST-elevation myocardial infarction following levodopa (Madopar) initiation.",
keywords = "Coronary artery disease, Levodopa, Myocardial infarction, Parkinson’s disease",
author = "Ng, {Chen Fei} and Tiau, {Patrick W.J.} and Tan, {Hui Jan} and {Mohamed Ibrahim}, Norlinah",
year = "2019",
month = "3",
day = "1",
doi = "10.4997/JRCPE.2019.108",
language = "English",
volume = "49",
pages = "37--39",
journal = "The journal of the Royal College of Physicians of Edinburgh",
issn = "1478-2715",
publisher = "Royal College of Physicians of Edinburgh",
number = "1",

}

TY - JOUR

T1 - Levodopa-induced myocardial infarction in a patient with Parkinson’s disease and severe coronary artery disease

AU - Ng, Chen Fei

AU - Tiau, Patrick W.J.

AU - Tan, Hui Jan

AU - Mohamed Ibrahim, Norlinah

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Levodopa is the most effective medical treatment for Parkinson’s disease (PD) to date. As dopamine is known to increase cardiac inotropism and vasomotor tone, peripheral dopamine decarboxylase inhibitor is coadministered to suppress the peripheral conversion of levodopa to dopamine. Levodopa poses potential cardiovascular risks, thus its use in patients with existing coronary artery disease needs to be carefully monitored. We report a case of an elderly male with newly diagnosed PD who developed non-ST-elevation myocardial infarction following levodopa (Madopar) initiation.

AB - Levodopa is the most effective medical treatment for Parkinson’s disease (PD) to date. As dopamine is known to increase cardiac inotropism and vasomotor tone, peripheral dopamine decarboxylase inhibitor is coadministered to suppress the peripheral conversion of levodopa to dopamine. Levodopa poses potential cardiovascular risks, thus its use in patients with existing coronary artery disease needs to be carefully monitored. We report a case of an elderly male with newly diagnosed PD who developed non-ST-elevation myocardial infarction following levodopa (Madopar) initiation.

KW - Coronary artery disease

KW - Levodopa

KW - Myocardial infarction

KW - Parkinson’s disease

UR - http://www.scopus.com/inward/record.url?scp=85062602471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062602471&partnerID=8YFLogxK

U2 - 10.4997/JRCPE.2019.108

DO - 10.4997/JRCPE.2019.108

M3 - Article

C2 - 30838990

AN - SCOPUS:85062602471

VL - 49

SP - 37

EP - 39

JO - The journal of the Royal College of Physicians of Edinburgh

JF - The journal of the Royal College of Physicians of Edinburgh

SN - 1478-2715

IS - 1

ER -